DexCom, Inc. (DXCM) ist ein börsennotiertes Unternehmen im Gesundheitswesen Sektor, tätig in der Medical - Devices Branche. Der Hauptsitz des Unternehmens ist in San Diego, CA, United States. Der aktuelle CEO ist Jacob Steven Leach.
DXCM hat IPO-Datum 2005-04-14, 10,200 Vollzeitbeschäftigte, gelistet an der NASDAQ Global Select, eine Marktkapitalisierung von $24.55B.
DexCom, Inc. is a medical device company headquartered in San Diego, California, specializing in the design, development, and commercialization of continuous glucose monitoring (CGM) systems for diabetes management. The company's product portfolio includes the DexCom G6 integrated CGM system, DexCom ONE for replacing traditional finger-stick blood glucose testing, DexCom Share for remote monitoring, and the Dexcom Real-Time API that enables third-party developers to integrate CGM data into digital health applications. DexCom markets its solutions directly to endocrinologists, physicians, diabetes educators, and healthcare providers across the United States and internationally, with the next-generation G7 system under development. The company also partners with Verily Life Sciences to develop advanced blood-based and interstitial glucose monitoring products.
